Vaccine development for Group B Neisseria meningitidis and Escherichia coli K1

今年这个项目没有完成任何工作。 针对B群脑膜炎球菌脑膜炎的疫苗开发因其荚膜多糖（PSA）而复杂化，所述荚膜多糖是与E. coli K1荚膜多糖和宿主结构，特别是在发育过程中。尽管有有效的抗生素和支持治疗，但全身感染，特别是由B群脑膜炎球菌和大肠杆菌K1引起的脑膜炎的死亡率和发病率仍然高得令人无法接受。B群脑膜炎双球菌（GBM）在世界范围内持续引起流行和暴发，E.大肠杆菌K1是新生儿脑膜炎和肾脏感染的主要原因。本研究的目的是检查证据或缺乏PSA抗体和自身免疫性疾病之间的关联。

No work was accomplished on this project this year. Vaccine development against group B meningococcal meningitis is complicated by its capsular polysaccharide (PSA), an a 2-8-linked poly-sialic acid that is identical to the surface saccharide of the E. coli K1 capsular polysaccharide and to host structures especially during development. Despite effective antibiotic and supportive therapy, the mortality and morbidity of systemic infections, especially of meningitis caused by group B meningococci and Escherichia coli K1, remain unacceptably high. Group B meningococci (GBM) continue to cause epidemics and outbreaks throughout the world and E. coli K1 is a major cause of neonatal meningitis and of kidney infections. The aim of this study is to examine evidence or the lack thereof of the association between PSA antibodies and autoimmune disease.